Review article · 2010
Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges
Expert Review of Pharmacoeconomics & Outcomes Research, 10(4), 407–420 · Published 1 August 2010 · DOI 10.1586/erp.10.45
In brief
“Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges” is a 2010 review article by Yanni Hao, published in Expert Review of Pharmacoeconomics & Outcomes Research. OpenAlex counts 20 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 20
- Most cited in
- 2016 (4)
- Field-weighted impact
- 0.36
- References
- 48
- Authors
- 1
Abstract
The US FDA has advocated the patient-reported outcome (PRO) draft guidance as the main vehicle for evaluating PRO-based labeling claims for oncology drugs. In addition, FDA-affiliated researchers have identified factors inhibiting acceptance of health-related quality of life (HRQoL)-based claims for oncology product labels. The views of the FDA on PRO claims are extensive and prescriptive.… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Hao, Y. (2010). Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges. Expert Review of Pharmacoeconomics & Outcomes Research, 10(4), 407–420. https://doi.org/10.1586/erp.10.45
MLA 9
Hao, Yanni. “Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges.” Expert Review of Pharmacoeconomics & Outcomes Research, vol. 10, no. 4, 2010, pp. 407–420. https://doi.org/10.1586/erp.10.45.
Chicago
Hao, Yanni. 2010. “Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges.” Expert Review of Pharmacoeconomics & Outcomes Research 10 (4): 407–420. https://doi.org/10.1586/erp.10.45.
Harvard
Hao, Y. (2010) ‘Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges’, Expert Review of Pharmacoeconomics & Outcomes Research, 10(4), pp. 407–420. doi:10.1586/erp.10.45.
IEEE
Y. Hao, “Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges,” Expert Review of Pharmacoeconomics & Outcomes Research, vol. 10, no. 4, pp. 407–420, 2010, doi: 10.1586/erp.10.45.
BibTeX
@article{hao2010patient,
title = {{Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges}},
author = {Hao, Yanni},
journal = {Expert Review of Pharmacoeconomics \& Outcomes Research},
year = {2010},
volume = {10},
number = {4},
pages = {407--420},
doi = {10.1586/erp.10.45},
url = {https://doi.org/10.1586/erp.10.45}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2012 | 3 | |
| 2013 | 2 | |
| 2014 | 3 | |
| 2015 | 2 | |
| 2016 | 4 | |
| 2017 | 1 | |
| 2018 | 1 | |
| 2020 | 1 | |
| 2022 | 2 | |
| 2023 | 1 |
Its field-weighted citation impact is 0.36: it has been cited 0.36 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- patient-reported outcomes
- health-related quality of life
- FDA draft guidance
- European Medicines Agency
- trial design
- missing data
Work with this paper
Most-cited papers in Economics, Econometrics and Finance
- Theory of the firm: Managerial behavior, agency costs and ownership structureMichael C. Jensen, William H. Meckling · Journal of Financial Economics · 1976 · 77,585 citations
- Institutions, Institutional Change and Economic PerformanceDouglass C. North · Cambridge University Press eBooks · 1990 · 34,377 citations
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.John E. Ware, Cathy Donald Sherbourne · PubMed · 1992 · 33,943 citations
- Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment EquationsManuel Arellano, Stephen R. Bond · The Review of Economic Studies · 1991 · 33,778 citations
- Co-Integration and Error Correction: Representation, Estimation, and TestingRobert F. Engle, C.W.J. Granger · Econometrica · 1987 · 32,847 citations
Questions about this paper
How do I cite this paper in APA style?
Hao, Y. (2010). Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges. Expert Review of Pharmacoeconomics & Outcomes Research, 10(4), 407–420. https://doi.org/10.1586/erp.10.45
How many times has this paper been cited?
20 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Yanni Hao.
What is the DOI of this paper?
10.1586/erp.10.45, permanently at https://doi.org/10.1586/erp.10.45. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.